Eva Montgomerie
Comptroller/Controller/Auditor at KAROLINSKA DEVELOPMENT AB
Network origin in Eva Montgomerie first degree
Entity | Entity type | Industry | |
---|---|---|---|
Public Company | Financial Conglomerates | 54 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Eva Montgomerie via their personal network
Company | Sector | Related people | Main position |
---|---|---|---|
Athera Biotechnologies AB
Athera Biotechnologies AB Pharmaceuticals: MajorHealth Technology Athera Biotechnologies AB operates as a biopharmaceutical company which focuses on developing targeted anti-inflammatory biological candidate drugs and companion diagnostics. It has a proprietary program the fully human antibody PC-mAb. The frim develops a biomarker and companion diagnostic CVDefine® kit. Its PC-mAb is a fully human monoclonal antibody which neutralizes a key driver of vascular inflammation, phosphorylcholine, which targets market of reducing secondary cardiovascular events, focusing on high-risk patients with low anti-PC levels. The company was founded by Johan Frostegard in 2002 and is headquartered in Stockholm, Sweden. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member Director of Finance/CFO Director/Board Member | |
MEDIVIR AB | Pharmaceuticals: Major | Director/Board Member Director/Board Member Chief Tech/Sci/R&D Officer Chief Tech/Sci/R&D Officer Chief Tech/Sci/R&D Officer | |
AstraZeneca AB
AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden. | Miscellaneous Commercial Services | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
SINO BIOPHARMACEUTICAL LIMITED | Pharmaceuticals: Major | Founder Corporate Officer/Principal Chairman Corporate Officer/Principal | |
Karolinska Institutet | College/University | Corporate Officer/Principal Doctorate Degree Chairman Corporate Officer/Principal Corporate Officer/Principal Doctorate Degree Corporate Officer/Principal Doctorate Degree Undergraduate Degree Corporate Officer/Principal Doctorate Degree Corporate Officer/Principal | |
OREXO AB | Pharmaceuticals: Major | Chief Executive Officer Director of Finance/CFO Chief Tech/Sci/R&D Officer Director/Board Member Corporate Officer/Principal | |
Stockholm School of Economics | College/University | Undergraduate Degree Undergraduate Degree Undergraduate Degree Masters Business Admin | |
University of Uppsala | College/University | Graduate Degree Graduate Degree | |
Karolinska Development AB (Private Equity)
Karolinska Development AB (Private Equity) Investment ManagersFinance Karolinska Development AB (Private Equity) (Karolinska Development) is a Venture Capital firm, a subsidiary of Karolinska Development AB founded in 2003. The firm is headquartered in Solna. | Investment Managers | Private Equity Investor Chief Executive Officer Chairman Private Equity Investor Chief Executive Officer Chief Executive Officer Director of Finance/CFO Chief Executive Officer Chief Executive Officer Chief Executive Officer Private Equity Investor Private Equity Investor Director of Finance/CFO Private Equity Analyst | |
Royal Institute of Technology | College/University | Corporate Officer/Principal Graduate Degree Graduate Degree | |
University of Lund | College/University | Corporate Officer/Principal Doctorate Degree Doctorate Degree Graduate Degree | |
Royal Swedish Academy of Engineering Sciences
Royal Swedish Academy of Engineering Sciences Miscellaneous Commercial ServicesCommercial Services The Royal Swedish Academy of Engineering Sciences (IVA) is an organization that brings together around 1,300 academy members and 250 companies to bridge the gap between academia, business, and politics. The non-profit company is based in Stockholm, Sweden. The Swedish company's aim is to work towards people's ability to contribute positively to society. The organization runs an internship program called Tekniksprånget, which gives young people in Sweden the opportunity to test the engineering profession through a four-month paid internship. The program has been running since 2012 and aims to inspire more people to choose a higher technical education. The CEO of the company is Björn O. Nilsson. | Miscellaneous Commercial Services | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
OxThera AB
OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden. | Pharmaceuticals: Generic | Director/Board Member Director/Board Member | |
KDev Exploratory AB
KDev Exploratory AB Miscellaneous Commercial ServicesCommercial Services KDev Exploratory AB provides drug discovery solutions. It performs discovery research in various therapeutic areas, such as screening in oncology, neuroscience, lead finding, characterization in inflammation and angiogenesis/age-related macular degeneration. The company was founded by David Jern in 2000 and is headquartered in Solna, Sweden. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member Chief Executive Officer Chairman | |
Biosergen AS
Biosergen AS BiotechnologyHealth Technology Biosergen AS develops drugs based on biosynthetic engineering of natural products, combined with chemical synthesis. It develops antibiotics for the use in antifungal therapy. The firm uses engineered biosynthesis technology that allows alterations in microbial genes, which lead to predictable changes in the final structure of the natural product. The company was founded in 2004 and is headquartered in Tiller, Norway. | Biotechnology | Director/Board Member Chief Executive Officer | |
Aprea Therapeutics AB
Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member Director/Board Member Director/Board Member Chief Executive Officer | |
PROMIMIC AB | Medical Specialties | Director/Board Member Corporate Officer/Principal Director/Board Member Director/Board Member | |
Dilafor AB
Dilafor AB Pharmaceuticals: MajorHealth Technology Dilafor AB develops pharmaceutical products from heparin derivatives with low anticoagulant activity. It investigates document and exploits the pharmacological properties of derivatives in the field of obstetrics. The company was founded by Gunvor Ester Ekman-Ordeberg, Hans-Peter Ekre, Per-Olov Eriksson, Per Giléus, Kjell Gunnarsson, Erik Yngve Holmer, Göran Kvist, Ulf Lindahl, Anders Malmström, Tore Mellstrand, Johan Rasin, and Mats Wahlgren in 2003 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Chairman Director/Board Member Founder | |
LIPIDOR AB | Miscellaneous Commercial Services | Director/Board Member Director/Board Member Director of Finance/CFO | |
KCIF Fund Management AB | Director/Board Member Director/Board Member Chief Executive Officer Chief Executive Officer Chairman Chief Executive Officer Director/Board Member | ||
Umecrine Cognition AB
Umecrine Cognition AB Pharmaceuticals: MajorHealth Technology Umecrine Cognition AB develops pharmaceuticals against neurological disorders in the central nervous system. The firm focuses on the development and commercialization of novel therapeutics to treat Hepatic Encephalopathy in patients with liver disease. The company was founded by Torbjörn Bäckström in 2006 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Chairman Director/Board Member Director/Board Member Director/Board Member Director of Finance/CFO | |
Akinion Pharmaceuticals AB
Akinion Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Akinion Pharmaceuticals AB operates as a holding company that focuses on the development of pharmaceutical for the treatment of acute myeloid leukemia. It develops, markets, and sells a product based on Biovitrum’s anti leukemia kinase inhibitor research. It is a drug development that manufactures a lead candidate drug, AKN-028, which is a small molecule kinase inhibitor. The company was founded by Vendela Parrow in 2009 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member Director/Board Member Chief Executive Officer Corporate Officer/Principal Chairman | |
ClanoTech AB
ClanoTech AB Pharmaceuticals: MajorHealth Technology ClanoTech AB is a holding company that develops drugs for the treatment of cancer and macular degeneration. Its lead candidate is an inhibitor of the alpha5beta1-integrin receptor which is present in fibroblast and on vascular endothelial cells. Its Alpha5beta1-integrin is strongly up-regulated in fibroblast when switching to the fibrotic state and in scars after glaucoma surgery. Its strategy spans from therapeutic areas with high commercial potential as wet Age Regulated Macular Degeneration to ophthalmology niche indications with orphan drug opportunity such as developing advent in glaucoma surgery techniques. The company was founded by Yihai Cao in 2006 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member Director/Board Member | |
NovaSAID AB
NovaSAID AB Pharmaceuticals: MajorHealth Technology NovaSAID AB develops treatments for inflammation and pain in conditions such as rheumatoid arthritis. It discovers selective microsomal prostaglandin E synthase-1 (mPGES-1), and has also demonstrated its effect in animal models for pain and inflammation. The firm's approach is to prevent the pathological formation of prostaglandin E2 (PGE2) selectively, through the development of inhibitors of mPGES-1, the enzyme that is responsible for the formation of PGE2 during inflammation. Its mPGES-1 inhibition offers an approach for inhibiting pathological PGE2 production without adversely affecting other important prostanoids. The company was founded by Per-Johan Göte Jakobsson, Ralf Morgenstern, Bertil Samuelsson and Bengt Ingemar Samuelsson on October 26, 2004 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Chairman Director/Board Member Chairman Chairman | |
NEOS AB | Medical Specialties | Director/Board Member Chairman Director/Board Member | |
SWEDISH ORPHAN BIOVITRUM AB | Pharmaceuticals: Major | Director/Board Member Chairman | |
Palette Life Sciences AB
Palette Life Sciences AB Medical SpecialtiesHealth Technology Palette Life Sciences AB operates as a pharmaceutical company. It specializes in developing products for local pain relief in obstetrics and gynecology. The company was founded by Berith Karlsson Tingåker, Gunvor Ekman-Ordeberg, Arne Folke Brodin and Lars Irestedt in 2009 and is headquartered in Solna, Sweden. | Medical Specialties | Director/Board Member Director/Board Member Director/Board Member | |
KDev Oncology AB
KDev Oncology AB Miscellaneous Commercial ServicesCommercial Services KDev Oncology AB offers research and development of new cancer treatments. It provides know-how in the field of oncology. The company was founded by David Jern on July 14, 2005 and is headquartered in Solna, Sweden. | Miscellaneous Commercial Services | Chief Executive Officer Director/Board Member Chairman Director/Board Member Chief Executive Officer Director/Board Member | |
OSSDSIGN AB | Medical Specialties | Director/Board Member Director/Board Member Director/Board Member | |
Stockholm School of Entrepreneurship | College/University | Chairman Director/Board Member | |
Modus Therapeutics AB
Modus Therapeutics AB Pharmaceuticals: MajorHealth Technology Modus Therapeutics AB operates as a clinical-stage drug development company that develops new pharmaceutical therapies designed to restore impaired blood flow and oxygen transport in diseases with unmet medical needs. The firm’s product Sevuparin, evaluates in a phase II clinical trial in sickle cell disease (SCD) and repeated painful crises in SCD, so called vaso-occlusive crises (VOC) that leads to loss of vital organ function and reduced life span. The company was founded by Carl Mats Wahlgren in 2011 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Chairman Director/Board Member Chief Executive Officer Director/Board Member | |
KD Incentive AB | Director/Board Member Director/Board Member Director/Board Member Director/Board Member Director/Board Member | ||
MODUS THERAPEUTICS HOLDING AB | Biotechnology | Chairman Director/Board Member Director/Board Member Director/Board Member Chief Executive Officer | |
KDev Investments AB
KDev Investments AB BiotechnologyHealth Technology KDev Investments AB engages in research, sales, and development in the fields of medicine, biotechnology, pharmaceuticals, and medical technology. It also owns and manages investments of companies in the fields of medicine. Its portfolio will include both early and clinical stage pharmaceutical assets, as well as some technology assets. The company was founded on January 10, 2012 and is headquartered in Solna, Sweden. | Biotechnology | Director/Board Member Director/Board Member Chairman Director/Board Member | |
The Wharton School of the University of Pennsylvania | College/University | Undergraduate Degree Undergraduate Degree | |
SYNACT PHARMA AB | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member Director/Board Member | |
Scibase AB | Director/Board Member Director/Board Member | ||
Svenska Vaccinfabriken Produktion AB
Svenska Vaccinfabriken Produktion AB BiotechnologyHealth Technology Svenska Vaccinfabriken Produktion AB develops vaccines and immunotherapies to prevent and treat life-threatening diseases. The company is based in Stockholm, Sweden. The Swedish company was founded by Matti Sällberg, Margaret Chen, Jens Bäck, Lars Frelin. Richard Bethell has been the CEO of the company since 2022. | Biotechnology | Director/Board Member Chief Executive Officer Director/Board Member | |
Arctic Asset Management AS (Sweden)
Arctic Asset Management AS (Sweden) Investment ManagersFinance Arctic Asset Management AS (Sweden) (AAM-Sweden) is the Sweden-based investment management arm of Arctic Asset Management AS, ultimately owned by Arctic Securities AS in Norway. The firm was founded in 2016 and is headquartered in Stockholm. AFM-Sweden manages portfolio of Nordic equities, Nordic fixed income and Global Life Science – through mutual funds and discretionary mandates for institutional clients, family offices, investment companies and private clients. | Investment Managers | Founder Chief Executive Officer Analyst-Equity | |
Gesynta Pharma AB
Gesynta Pharma AB Pharmaceuticals: MajorHealth Technology Gesynta Pharma AB develops and manufactures novel oral treatments for patients with chronic inflammatory conditions. The company was founded by Gunilla Anders Ekström, Charlotte Elisabet Edenius, Urban Paulsson, Ralf Morgenstern, Per-Johan Göte Jakobsson and Patric Stenberg in 2017 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Founder Founder | |
AnaCardio AB
AnaCardio AB Pharmaceuticals: MajorHealth Technology AnaCardio AB is a clinical stage biopharmaceutical company based in Stockholm, Sweden. AnaCardio develops drugs targeting a novel mechanism that improves cardiac contractility to treat heart failure, a progressive cardiac syndrome affecting more than six million individuals in the US and nearly 100 million worldwide. The Swedish company's unique solution is based on the ghrelin signaling pathway, intended to increase contractility without causing adverse tachycardia, arrhythmia, ischemia, or hypotension. The company was founded by Lars Lund and is currently led by CEO Patrik Strömberg since 2021. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member | |
invoX Pharma Ltd.
invoX Pharma Ltd. Pharmaceuticals: MajorHealth Technology Part of Sino Biopharmaceutical Ltd., invoX Pharma Ltd. is a British biopharmaceutical company. The private company is based in Kingston-upon-Thames, UK. The company was founded in 2021. Benjamin Toogood has been the CEO of the company since 2023. | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member Chief Investment Officer |
Statistics
International
Sweden | 46 |
Hong Kong | 2 |
Denmark | 2 |
Norway | 2 |
United States | 2 |
Sectoral
Health Technology | 30 |
Commercial Services | 9 |
Consumer Services | 8 |
Finance | 4 |
Operational
Director/Board Member | 490 |
Corporate Officer/Principal | 146 |
Chairman | 134 |
Independent Dir/Board Member | 79 |
Chief Executive Officer | 69 |
Most connected contacts
Insiders | |
---|---|
Gunnar Magnus Modee Persson | 51 |
Ping Tse | 43 |
Viktor Drvota | 41 |
Peter Sjöstrand | 35 |
Bo Jesper Hansen | 34 |
Stig Lennart Hansson | 32 |
Michael Wilhelm Rosenlew | 32 |
Sten Gunnar Otto Skolling | 32 |
Per Gunnar Ernst Aniansson | 31 |
Hans Lennart Rudolf Wigzell | 30 |
Khalid Islam | 29 |
Torbjørn Bjerke | 27 |
Michael Owens | 25 |
Karl Härfstrand | 23 |
Jim van Heusden | 22 |
- Stock Market
- Insiders
- Eva Montgomerie
- Company connections